Skip to main content
. 2023 Aug 14;11:1187253. doi: 10.3389/fcell.2023.1187253

FIGURE 1.

FIGURE 1

Effect of Gpr18 agonist on mouse and human myogenesis. (A) Western blot on mdx myoblasts treated with PSB-KD107 (10 μM) for 0, 5, 15, 30, 60, 120 min showing the expression of p-Akt, total Akt, and GAPDH (experiment performed in biological duplicates with similar results). (B) Representative micrographs of Myosin Heavy chain (MyHC, green) and DAPI (nuclei, blue), and (C) quantification of fusion index in mdx myoblasts differentiated 4 days and treated with Resolvin-D2 (RvD2; 200 nM), PSB-KD107 (10 μM), or vehicle. n = 3 independent biological samples from different mdx mice. (D) Representative micrographs showing the time course differentiation of hiPSC into myogenic cells. (E) Western blot showing the expression of GPR18 in proliferating and differentiating DMD hiPSC-derived myoblasts (experiments performed in technical duplicates with similar results). (F) Proliferation curve of DMD hiPSC-derived myoblasts treated with PSB-KD107, RvD2, or vehicle. (G) Representative micrographs of MyHC (red) and DAPI (blue), and (H) quantification of the fusion index of DMD hiPSC-derived myoblasts differentiated 7 days and treated with PSB-KD107, RvD2, or vehicle. n = 3 independent biological samples from different patients. Results shown as mean+/- SEM. *p < 0.05 (One-Way ANOVA with Fisher LSD post hoc test).